Indoleamine 2,3-dioxygenase 1 Activation in Mature CDC1 Promotes Tolerogenic Education of Inflammatory CDC2 Via Metabolic Communication
Overview
Authors
Affiliations
Conventional dendritic cells (cDCs), cDC1 and cDC2, act both to initiate immunity and maintain self-tolerance. The tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is used by cDCs in maintaining tolerance, but its role in different subsets remains unclear. At homeostasis, only mature CCR7 cDC1 expressed IDO1 that was dependent on IRF8. Lipopolysaccharide treatment induced maturation and IDO1-dependent tolerogenic activity in isolated immature cDC1, but not isolated cDC2. However, both human and mouse cDC2 could induce IDO1 and acquire tolerogenic function when co-cultured with mature cDC1 through the action of cDC1-derived l-kynurenine. Accordingly, cDC1-specific inactivation of IDO1 in vivo exacerbated disease in experimental autoimmune encephalomyelitis. This study identifies a previously unrecognized metabolic communication in which IDO1-expressing cDC1 cells extend their immunoregulatory capacity to the cDC2 subset through their production of tryptophan metabolite l-kynurenine. This metabolic axis represents a potential therapeutic target in treating autoimmune demyelinating diseases.
Aromatic Amino Acid Metabolites: Molecular Messengers Bridging Immune-Microbiota Communication.
Shin H, Bang Y Immune Netw. 2025; 25(1):e10.
PMID: 40078785 PMC: 11896664. DOI: 10.4110/in.2025.25.e10.
Narasimhan H, Richter M, Shakiba R, Papaioannou N, Stehle C, Ravi Rengarajan K Proc Natl Acad Sci U S A. 2025; 122(9):e2417308122.
PMID: 39993193 PMC: 11892598. DOI: 10.1073/pnas.2417308122.
Dendritic cell maturation in cancer.
Moon C, Belabed M, Park M, Mattiuz R, Puleston D, Merad M Nat Rev Cancer. 2025; .
PMID: 39920276 DOI: 10.1038/s41568-024-00787-3.
Harnessing amino acid pathways to influence myeloid cell function in tumor immunity.
Pan J, Lin Y, Liu X, Zhang X, Liang T, Bai X Mol Med. 2025; 31(1):44.
PMID: 39905317 PMC: 11796060. DOI: 10.1186/s10020-025-01099-4.
Cross-priming in cancer immunology and immunotherapy.
Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .
PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.